Category:
Active Pharmaceutical Ingredients
CAS NO:
NA
Standard:
ChP,
Research and development(R&D)
Dabrafenib and Trametinib are targeted oncology agents for BRAF V600E mutation-positive melanoma. The combination inhibits MAPK pathway signaling via MEK1/2 blockade. Key identifiers include CAS 871704-10-6 (Dabrafenib) and CAS 871705-13-6 (Trametinib). Molecular formulas: C21H19ClF3N5O2 and C29H28N4O4 respectively.
Contraindicated in patients with VEPRA mutations or uncontrolled hypertension. Store APIs at controlled room temperature (20-25°C) in moisture-proof containers. Strict adherence to GMP guidelines is mandatory during synthesis and packaging to ensure potency stability.